Quick Answer
VERTEX PHARMACEUTICALS INC / MA reported R&D Expense of $3.05 billion for fiscal year 2021.
VERTEX PHARMACEUTICALS INC / MA R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2021 | $3.05B | +66.8% |
| 2020 | $1.83B | +4.3% |
| 2019 | $1.75B | +23.9% |
| 2018 | $1.42B | +6.9% |
| 2017 | $1.32B | +26.4% |
| 2016 | $1.05B | +5.2% |
| 2015 | $995.92M | +16.4% |
| 2014 | $855.51M | -3.0% |
| 2013 | $882.10M | +15.2% |
| 2012 | $765.90M | +8.2% |
| 2011 | $707.71M | +11.0% |
| 2010 | $637.42M | +15.8% |
| 2009 | $550.27M | +6.5% |
| 2008 | $516.91M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| March 31, 2022 | $603.10M | +32.3% | +22.1% |
| September 30, 2021 | $493.75M | +0.1% | -64.9% |
| June 30, 2021 | $1.41B | +234.3% | +208.6% |
| March 31, 2021 | $456.00M | +1.7% | -7.6% |
| September 30, 2020 | $493.50M | -11.2% | +17.2% |
| June 30, 2020 | $420.93M | +11.0% | -6.2% |
| March 31, 2020 | $448.53M | +32.1% | -19.3% |
| September 30, 2019 | $555.95M | +68.2% | +46.7% |
- VERTEX PHARMACEUTICALS INC / MA showed an increase of +66.8% in R&D Expense compared to the prior fiscal year.
- Over the 2008–2021 period, VERTEX PHARMACEUTICALS INC / MA’s r&d expense has grown by 490.3% (from $516.91 million to $3.05 billion).
- The most recent figure is from VERTEX PHARMACEUTICALS INC / MA’s fiscal year 2021 report (Form 10-K), filed with the SEC on February 9, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: